REG - Yourgene Health PLC - Directors' dealing & warrant extension
RNS Number : 4353YYourgene Health PLC09 May 2019Yourgene Health plc
("Yourgene," the "Company")
Directors' dealing and warrant extension
Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified yesterday by Barry Hextall and Hayden Jeffreys, both directors of the Company, that they respectively purchased 89,551 and 222,348 ordinary shares of 0.10p each in the Company yesterday at an average price of 11.2 pence per ordinary share. The table below details each directors' shareholdings:
Director
Shareholding prior to purchase of shares
Number of ordinary shares purchased
Shareholding following purchase of shares
Ordinary shares held as percentage of issued voting share capital
Barry Hextall
432,518
89,551
522,069
0.09%
Hayden Jeffreys
0
222,348
222,348
0.04%
Extension of warrant
Furthermore, the Company announces that it has agreed to extend the exercise period by a year of a warrant granted over 1,411,227 ordinary shares that was scheduled to expire on 13 June 2019.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
Tel: +44 (0)16 1667 1053
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
Tel: +44 (0)20 7213 0880
Stifel Nicolaus Europe Limited (Broker)
Nicholas Moore / Matthew Balwat / Ben Maddison
Tel: +44 (0)20 7710 7600
Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
Tel: +44 (0)20 7390 0234
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.
Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
(i) Barry Hextall
(ii) Hayden Jeffreys
2
Reason for notification
a.
Position/Status
(i) Chief Financial Officer
(ii) Chief Operating Officer
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Yourgene Health plc
b.
LEI
213800UUIT8BZE7QEH33
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification CodeOrdinary shares of 0.10p each
ISIN: GB00BN31ZD89
b.
Nature of the transaction
Purchase of ordinary shares
c.
Price(s) and volume(s)
Price(s)
Volume(s)
(i) 11.5p
(ii) 11.5p
(i) 89,551
(ii) 222,348
d.
Aggregated information
- Aggregated Volume
- Price
311,899
11.5p
e.
Date of the transaction
8 May 2019
f.
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHKMGGKVRGGLZM
Recent news on Yourgene Health
See all newsREG - Velay Financial - Form 8.3 - YOURGENE HEALTH PLC
AnnouncementREG - AIM Yourgene Health PLC - Cancellation - Yourgene Health plc
AnnouncementREG - Yourgene Health PLC - De-listing and cancellation of trading of Shares
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement